Form 8-K - Current report:
SEC Accession No. 0001398733-25-000016
Filing Date
2025-09-04
Accepted
2025-09-04 07:11:06
Documents
17
Period of Report
2025-09-04
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K aqst-20250904.htm   iXBRL 8-K 27657
2 EX-99.1 adcompressrelease-9x3x25.htm EX-99.1 13876
6 adcompressrelease-9x3x25001.jpg GRAPHIC 216454
7 adcompressrelease-9x3x25002.jpg GRAPHIC 252176
8 adcompressrelease-9x3x25003.jpg GRAPHIC 287848
9 adcompressrelease-9x3x25004.jpg GRAPHIC 224731
  Complete submission text file 0001398733-25-000016.txt   1514381

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT aqst-20250904.xsd EX-101.SCH 1776
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT aqst-20250904_lab.xml EX-101.LAB 21629
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT aqst-20250904_pre.xml EX-101.PRE 12504
19 EXTRACTED XBRL INSTANCE DOCUMENT aqst-20250904_htm.xml XML 2719
Mailing Address 30 TECHNOLOGY DRIVE WARREN NJ 07059
Business Address 30 TECHNOLOGY DRIVE WARREN NJ 07059 908-941-1900
Aquestive Therapeutics, Inc. (Filer) CIK: 0001398733 (see all company filings)

EIN.: 208623253 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38599 | Film No.: 251291880
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)